With plans to file the T-cell receptor (TCR) therapy afamitresgene autoleucel (afami-cel) for US Food and Drug Administration approval in the fourth quarter of 2022, Adaptimmune Therapeutics plc is looking ahead to commercialization in 2023. Afami-cel, a TCR therapy targeted to MAGE-A4, could be one of the first cell therapies to win FDA approval for a solid tumor indication, though it is a very small one.
CEO Adrian Rawcliffe said the company hopes to leverage existing industry experience with CAR-T cell therapies while targeting an ultra-orphan indication, synovial carcinoma